OpenNashEarnings

Pharmaceuticals · NYSE: TAK

Takeda earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends March · next results expected around 28 Jan 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q2 FY2026

Takeda's growth leaned on subcutaneous ENTYVIO and immunoglobulin demand, while new launches grew 17.3% at constant exchange rates but remain a small share of the business.

Demand centered on gastroenterology and plasma-derived therapies. ENTYVIO grew with the subcutaneous formulation in the U.S. and Europe, and subcutaneous immunoglobulins CUVITRU and HYQVIA grew at double-digit rates. Newer products added momentum: LIVTENCITY, VONVENDI, ADZYNMA, FRUZAQLA and QDENGA each grew on launch or expanded-use gains. TRINTELLIX benefited from U.S. pricing and payer mix. Takeda also discontinued its cell therapy research.

Read the Q2 FY2026 summary →

Quarters

KPI history

20-F filings